Entering text into the input field will update the search result below

Iveric Bio price target raised at Morgan Stanley ahead of clinical data in Q3

  • Iveric Bio (NASDAQ:ISEE) garnered gains until noon trading today after Morgan Stanley raised its price target on the stock to $30 from $25 amidst favorable risk/reward ahead of Phase 3 GATHER2 Data in Q3 of 2022.
  • Iveric said it expects

Recommended For You

Comments (1)

Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

mookdoc profile picture
She will be obsolete before you can blink! Good work MS!

Related Stocks

SymbolLast Price% Chg
IVERIC bio, Inc.
Apellis Pharmaceuticals, Inc.
NGM Biopharmaceuticals, Inc.
Power Solutions International, Inc.
ContraFect Corporation
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.